banner
Dehydrogenase inhibitor, Taribavirin, Purity ≥98%
Inquiry

Cat. No.: X24-09-YM218

Dehydrogenase inhibitor, Taribavirin, Purity ≥98%

Synonym: 119567-79-2; Viramidine; Ribamidine; Ribavirin amidine; Taribavirin free base; 1-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide; Dehydrogenase inhibitor

  • CAS Number: 119567-79-2
  • Compound CID: 451448
img
Product Size
1 mg; 5 mg; 10 mg; 20 mg
Price
Datasheet
MSDS
Properties
Description
Taribavirin is an effective metabolism inhibitor, that has the ability to prevent the pathway of cell metabolism by inhibiting dehydrogenases. The molecular weight of the compound is 243.22, and its molecular formula is C8H13N5O4.
Molecular Weight
243.22
Molecular Formula
C8H13N5O4
Form
Lyophilized powder
Purity
≥98%
Impurities
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects.
Identity
Confirmed by NMR/HPLC/MS.
Applications
Taribavirin plays a key role in inhibiting viral RNA polymerase, thereby disrupting the replication of the virus.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0